{"nctId":"NCT01086150","briefTitle":"Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy","startDateStruct":{"date":"2009-10"},"conditions":["Diabetic Peripheral Neuropathy"],"count":51,"armGroups":[{"label":"Healthy control patients","type":"OTHER","interventionNames":["Procedure: Skin biopsy","Drug: Lidocaine 5% patches"]},{"label":"Type I or Type II diabetes with painful diabetic neuropathy","type":"OTHER","interventionNames":["Procedure: Skin biopsy","Drug: Lidocaine 5% patches"]},{"label":"patients with non-painful diabetic peripheral neuropathy","type":"OTHER","interventionNames":["Procedure: Skin biopsy","Drug: Lidocaine 5% patches"]}],"interventions":[{"name":"Skin biopsy","otherNames":[]},{"name":"Lidocaine 5% patches","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Group 1: 18-70 years of age, non-diabetic with no nervous system disease (healthy control group)\n* Group 2: 18-70 years of age with Type I or Type II diabetes with significantly painful diabetic neuropathy (VAS \\> 40mm at Baseline)\n* Group 3: 18-70 years of age with Type I or Type II diabetes with non- painful or insignificantly painful diabetic neuropathy (VAS \\< 40mm at Baseline)\n\nExclusion Criteria:\n\n* History of clinically significant liver disease, serious peripheral vascular disease, a blood clotting disorder, or any other medical condition felt to be exclusionary by the investigator\n* Allergy to lidocaine\n* Unwillingness to sign informed consent or any other reasons for which the investigator feels the subject cannot complete the study\n* Women who are pregnant, breastfeeding or trying to become pregnant\n* History of slow-healing diabetic foot ulcers\n* Current skin or soft tissue lesions on the foot that will interfere with application of the lidocaine patch and or skin biopsies\n* Subjects taking Class I antiarrhythmics\n* HgA1c \\> 11%\n* Active cancer within the previous two years except treated basal cell carcinoma of the skin\n* Co-morbidities that can produce neuropathy\n* Subjects taking sodium channel blockers within one week of study treatment and throughout the study\n* Subjects taking any other experimental drugs within 30 days prior to Screening Visit (Visit 1)\n* Application of lidocaine patch to either foot within two weeks of Screening Visit (Visit 1)","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain Scores From Composite Visual Analog Scale","description":"Scores range from 0 to 10 with higher scores indicating higher levels of pain.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"6.5","spread":null},{"groupId":"OG002","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Keratinocyte Immunoreactivity of Nav1.6, Nav1.7, CGRP","description":"Pixel intensity (0-256) of immunofluorescence for each individual biomarker.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"101.4","spread":null},{"groupId":"OG002","value":"87.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"90.7","spread":null},{"groupId":"OG002","value":"90.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":null},{"groupId":"OG001","value":"59.6","spread":null},{"groupId":"OG002","value":"54.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"51.5","spread":null},{"groupId":"OG002","value":"54.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"38.5","spread":null},{"groupId":"OG002","value":"29.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":null},{"groupId":"OG001","value":"32.8","spread":null},{"groupId":"OG002","value":"26.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":[]}}}